Obinutuzumab (brand name Gazyva®/Gazyvaro®) is a humanized, glycoengineered type II anti-CD20 monoclonal antibody of the IgG1 isotype. Its Fc region is engineered to reduce fucose content, which enhances binding to FcγRIIIa on immune effector cells (e.g., natural killer cells, macrophages), resulting in stronger antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) compared to earlier anti-CD20 antibodies like rituximab. As a type II antibody, it also induces direct, non-apoptotic cell death with weaker complement-dependent cytotoxicity (CDC). It is approved in combination with chemotherapy for the treatment of follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL), and for previously untreated advanced FL in combination with bendamustine followed by obinutuzumab maintenance.